- ISIN
- US23285D1090
- CUSIP
- 23285D109
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Jul 23, 2021
Highlights
- Market Cap
- $521.25M
- Enterprise Value
- $469.42M
- EPS (TTM)
- -$0.58
- Total Revenue (TTM)
- $204.17M
- Gross Profit (TTM)
- $105.56M
- EBITDA (TTM)
- -$26.31M
- Year Range
- $2.90 - $6.18
- Target Price
- $6.00
- ROA (TTM)
- -16.48%
- ROE (TTM)
- -22.59%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CTKB Performance Chart
Cytek Biosciences, Inc. (CTKB) is down 19.8% since the beginning of the year. At $4 per share, CTKB is trading 34.5% below its 52-week high of $6.
Loading charts...
Returns By Period
Cytek Biosciences, Inc. (CTKB) has returned -19.80% so far this year and 42.11% over the past 12 months.
Cytek Biosciences, Inc.
- 1D
- -3.34%
- 1M
- -13.09%
- YTD
- -19.80%
- 6M
- -24.44%
- 1Y
- 42.11%
- 3Y*
- -20.53%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
CTKB Monthly Returns History
Based on dividend-adjusted daily data since Jul 23, 2021, CTKB's average daily return is -0.04%, while the average monthly return is -0.98%.
Historically, 38% of months were positive and 62% were negative. The best month was Nov 2023 with a return of +64.9%, while the worst month was May 2023 at -32.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CTKB closed higher 48% of trading days. The best single day was Nov 6, 2024 with a return of +36.0%, while the worst single day was May 10, 2023 at -24.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.99% | -10.40% | -2.46% | 4.35% | -8.11% | -3.34% | -19.80% | ||||||
| 2025 | -20.65% | -12.82% | -10.69% | -7.48% | -25.34% | 22.74% | 5.88% | 15.00% | -16.18% | 12.39% | 44.87% | -10.62% | -22.19% |
| 2024 | -17.21% | 1.99% | -12.86% | -10.43% | -6.32% | -0.89% | 20.25% | -14.46% | -3.48% | -10.74% | 32.05% | -0.61% | -28.84% |
| 2023 | 18.02% | -14.52% | -10.78% | 24.92% | -31.97% | 9.35% | 4.92% | -15.18% | -27.37% | -23.73% | 64.85% | 31.41% | -10.68% |
| 2022 | -10.78% | -6.32% | -20.97% | -12.34% | 2.75% | 10.50% | 19.29% | -8.98% | 26.35% | 5.43% | -16.95% | -20.79% | -37.44% |
| 2021 | 18.23% | 2.71% | -6.01% | 6.54% | -11.57% | -19.09% | -13.01% |
Benchmark Metrics
Cytek Biosciences, Inc. has an annualized alpha of -24.42%, beta of 1.41, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since July 26, 2021.
- This stock participated in 183.09% of S&P 500 Index downside but only 32.97% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -24.42%
- Beta
- 1.41
- R²
- 0.13
- Upside Capture
- 32.97%
- Downside Capture
- 183.09%
Return for Risk
Risk / Return Rank
CTKB ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cytek Biosciences, Inc. (CTKB) and compare them to S&P 500 Index.
| CTKB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.56 | ||
| Sortino ratioReturn per unit of downside risk | -1.67 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.41 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | 0.99 | 2.93 | -1.94 |
| Martin ratioReturn relative to average drawdown | 2.48 | 13.52 | -11.04 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cytek Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cytek Biosciences, Inc. was 91.34%, occurring on May 23, 2025. The portfolio has not yet recovered.
The current Cytek Biosciences, Inc. drawdown is 85.50%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -91.34%May 2025 | 3y 8mo | — | 4y 8moSep 2021 - now |
2021 bear market2021 | -24.91%Aug 2021 | 19d | 16d | 1mo 5dAug 2021 - Sep 2021 |
2021 pullback2021 | -6.61%Jul 2021 | 1d | 1d | 2dJul 2021 - Jul 2021 |
2021 pullback2021 | -6.03%Aug 2021 | 1d | 5d | 6dAug 2021 - Aug 2021 |
Drawdown Indicators
| CTKB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.34% | -56.78% | -34.56% |
Max Drawdown (1Y)Largest decline over 1 year | -42.94% | -9.10% | -33.84% |
Max Drawdown (3Y)Largest decline over 3 years | -74.55% | -18.90% | -55.65% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -85.50% | -0.74% | -84.76% |
Average DrawdownAverage peak-to-trough decline | -67.89% | -10.72% | -57.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.00% | 1.97% | +15.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cytek Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cytek Biosciences, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CTKB relative to other companies in the Medical Devices industry. Currently, CTKB has a P/S ratio of 2.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CTKB in comparison with other companies in the Medical Devices industry. Currently, CTKB has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CTKB
Add Cytek Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CTKB